Dr. Leslie Lehmann, MD

Claim this profile

Boston Children's Hospital (pediatric patients)

Studies Bone Marrow Failure Syndrome
Studies Aplastic Anemia
4 reported clinical trials
9 drugs studied

Area of expertise

1Bone Marrow Failure Syndrome
Leslie Lehmann, MD has run 2 trials for Bone Marrow Failure Syndrome. Some of their research focus areas include:
SAMD9 positive
SAMD9L positive
GATA2 positive
2Aplastic Anemia
Leslie Lehmann, MD has run 1 trial for Aplastic Anemia.

Affiliated Hospitals

Image of trial facility.
Boston Children's Hospital (pediatric Patients)
Image of trial facility.
Boston Children's Hospital

Clinical Trials Leslie Lehmann, MD is currently running

Image of trial facility.

Lung Injury

for Pediatric Bone Marrow Transplant

Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy and pulmonary morbidity affects as many as 25% of children receiving transplant. Early pulmonary injury includes diffuse alveolar hemorrhage (DAH), thrombotic microangiopathy (TMA) interstitial pneumonitis (IPS) and infection, while later, bronchiolitis obliterans is a complication of chronic GVHD associated with severe morbidity and mortality. Improved diagnosis and treatment of pulmonary complications are urgently needed as survival after HSCT improves, and as HSCT is increasingly used for non-malignant disorders such as sickle cell disease. Currently, there are large and important gaps in the investigator's knowledge regarding incidence, etiology and optimal treatment of pulmonary complications. Moreover, young children unable to perform spirometry are often diagnosed late, and strategies for monitoring therapeutic response are limited. This is a prospective multi-institutional cohort study in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). Assembly of a large prospective uniformly screened cohort of children receiving HSCT, together with collection of biological samples, will be an effective strategy to identify mechanisms of lung injury, test novel diagnostic strategies for earlier diagnosis, and novel treatments to reduce morbidity and mortality from lung injury after transplant.
Recruiting1 award N/A1 criteria
Image of trial facility.

Xylitol Wipes

for Bloodstream Infections in Stem Cell Transplant Patients

Bloodstream infections (BSI) caused by bacteria translocating across injured oral mucosa are a significant cause of morbidity and mortality in patients undergoing stem cell transplantation (SCT). Unfortunately, there are currently no known strategies to prevent these BSI in this vulnerable population. The investigators will conduct a randomized, double-blind, placebo-controlled trial at three institutions to evaluate the effectiveness of twice daily intraoral xylitol-wipe application on reducing BSI in pediatric SCT patients.
Recruiting0 awards Phase 2

More about Leslie Lehmann, MD

Clinical Trial Related3 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Leslie Lehmann, MD has experience with
  • Fludarabine
  • Alemtuzumab
  • Cyclosporins
  • Mycophenolate Mofetil
  • Tacrolimus
  • Thymoglobulin (Rabbit Anti-thymocyte Globulin; RATG)

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Leslie Lehmann, MD specialize in?
Is Leslie Lehmann, MD currently recruiting for clinical trials?
Are there any treatments that Leslie Lehmann, MD has studied deeply?
What is the best way to schedule an appointment with Leslie Lehmann, MD?
What is the office address of Leslie Lehmann, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security